Ketone-DNA: A Versatile Postsynthetic DNA Decoration Platform
摘要:
[GRAPHICS]A general strategy for the functional diversification of DNA, oligonucleotides under physiological conditions was developed. We describe the synthesis of DNA molecules bearing ketone ports (ketone-DNA) and the efficient postsynthetic decoration of ketone-DNA with structurally diverse aminooxy compounds.
A cysteine-appended deoxyuridine for the postsynthetic DNA modification using native chemical ligation
摘要:
A new deoxyuridine derivative 6 bearing a cysteine group at the C5 position was synthesized and incorporated into oligodeoxynucleotide (ODN) by phosphoramidite chemistry. The postsynthetic DNA modification of the cysteine-containing ODN using native chemical ligation with thioesters of biotin and green fluorescent protein variant was successfully demonstrated. (c) 2005 Elsevier Ltd. All rights reserved.
The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.
该申请公开了抑制替代补体途径的方法和组合物。该申请进一步提供了用于治疗干性老年性黄斑变性、地理萎缩、湿性老年性黄斑变性或斯塔加特病的抗因子 D 合剂。
Compositions with improved intravitreal half-life and uses thereof
申请人:Vitrisa Therapeutics, Inc.
公开号:US10308943B2
公开(公告)日:2019-06-04
Provided herein are compositions and methods for the treatment of retinal diseases. The compositions and methods include a therapeutic agent conjugated to a vitreous component binding moiety. The vitreous component binding moiety may be an aptamer or a small molecule that binds to a structural component of the vitreous humor (e.g., hyaluronic acid, collagen or vitronectin).
Stem-loop compositions and methods for inhibiting factor D
申请人:Vitrisa Therapeutics, Inc.
公开号:US10428330B2
公开(公告)日:2019-10-01
The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.
该申请公开了抑制替代补体途径的方法和组合物。该申请进一步提供了用于治疗干性年龄相关性黄斑变性、地理萎缩、湿性年龄相关性黄斑变性或斯塔加特病的抗因子 D 配合物。在某些情况下,提供了用于抑制因子 D 的干环适配体。
Compositions and methods for inhibiting factor D
申请人:396419 B.C. Ltd.
公开号:US11274307B2
公开(公告)日:2022-03-15
The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.
该申请公开了抑制替代补体途径的方法和组合物。该申请进一步提供了用于治疗干性老年性黄斑变性、地理萎缩、湿性老年性黄斑变性或斯塔加特病的抗因子 D 合剂。